Bibliography
- Lindner MD, McArthur RA, Deadwyler SA, Development, optimization and use of preclinical behavioral models to maximize the productivity of drug discovery for Alzheimer's disease. In: McArthur RA, Borsini F, editors. Animal and Translational Models for CNS Drug Discovery: Neurologic Disorders. Academic Press; San Diego: 2008. p. 93-157
- Aisen PS, Andrieu S, Sampaio C, Report of the task force on designing clinical trials in early (preclinical) dementia. Neurology 2011;76:280-6
- Paul SM, Mytelka DS, Dunwiddle CT, How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;5:203-14
- Klein DF. The loss of serendipity in psychopharmacology. JAMA 2008;299:1063-5
- Lansbury PT. Back to the future: the ‘old fashioned' way to new medications for neurodegenerations. Nat Med. 2004 Jul;10 Suppl:S51-7. Available From: http://www.ncbi.nlm.nih.gov/pubmed?term=Lansbury%20PT%20Back%20to%20the%20future
- Schneider LS, Lahiri DK. The perils of Alzheimer's drug development. Curr Alzheimer Res 2009;6:77-9
- Cogger KO. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs. J Clin Psychopharmacol 2007;27:418-20
- Demitrack MA, Faries D, Herrera JM, The problem of measurement error in multisite clinical trials. Psychopharmacol Bull 1998;34:19-24
- Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer's Dement 2009;5:388-97
- Becker RE, Greig NH. Fire in the ashes: can failed Alzheimer's drugs succeed with second chances? Alzheimer's Dement 2012; In press
- Reason J. Human Error. Cambridge University Press; Cambridge: 1990
- Becker RE, Markwell S. Problems arising from the generalizing of treatment efficacy from clinical trials in Alzheimer's disease. Clin Drug Investig 2000;19:33-41
- Becker RE, Greig NH. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res 2008;5:347-57
- Becker RE, Greig NH. Neuropsychiatric clinical trials: lost in translation. Sci Transl Med 2:61- p. 61rv6; DOI: 10.1126/scitranslmed.3000446, 2010
- Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007;6:521-32
- Markou A, Chiamulera C, Geyer MA, Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009;34:74-89
- Kahneman D. Thinking, Fast and Slow. Farrrar, Straus and Giroux; New York: 2012. p. 209-12
- Neurath O. Philosophical Papers 1913-1946. In: Cohen RS, Neurath M. editors. Reidel; Dordrecht: 1983. p. 92